Why Insulet (PODD) is a Top Growth Stock for the Long-Term

Insulet is projected to deliver 31% year-over-year earnings growth in the current fiscal year, while its fiscal 2026 consensus EPS estimate rose $0.06 to $6.51 after seven upward analyst revisions in 60 days. The insulin-delivery company has a Zacks Rank #3 (Hold), Growth Score of B and VGM Score of B, and has averaged a 13.6% earnings surprise. The favorable estimate-revision trend supports a constructive long-term view, though the Hold rating limits the immediacy of the call.

Analysis

This is low-information promotional research rather than a fundamental catalyst, so it should not independently move PODD. The relevant signal is modest upward estimate drift, but a $0.06 change to forward EPS is too small to underwrite a rerating without confirmation that it reflects accelerating Omnipod starts, international penetration, or improved gross margin rather than routine model maintenance. Near term, PODD is more likely to trade on the next earnings print and management's volume/gross-margin guide than on sell-side rankings.

The more important competitive question is whether tubeless pump adoption is taking share from Medtronic (MDT) and Tandem (TNDM), or merely expanding the pump category. If PODD's growth is share-led, TNDM is the cleanest negative read-through given its smaller installed base and greater operating leverage; if it is category-led, CGM ecosystems at DexCom (DXCM) and Abbott (ABT) also benefit through sensor utilization. Over 6-18 months, reimbursement coverage and integration with automated insulin-delivery software matter more than a single-year earnings-growth rate, because they determine recurring consumables revenue and retention.

Contrarian risk is valuation asymmetry: high-quality diabetes-device growth commonly prices in sustained execution, leaving limited tolerance for a deceleration in new patient adds or manufacturing/FX pressure. A positive earnings surprise alone is insufficient if forward revenue or gross-margin guidance does not rise. NNOX has no fundamental linkage to the PODD thesis; its inclusion appears promotional and should be ignored.

Key Decisions for Investors

• No immediate trade on the article. Place PODD on an earnings watchlist for the next 1-3 months; initiate only if management raises full-year revenue and gross-margin guidance while reporting accelerating U.S. and international customer additions.
• Conditional pair: long PODD / short TNDM over a 3-6 month horizon if channel checks show tubeless pump share gains. Size modestly because both are exposed to diabetes-device utilization and reimbursement; exit if TNDM stabilizes its new-patient growth or PODD's share gains fail to appear in quarterly disclosures.
• For existing PODD longs, use a guidance-based risk trigger rather than the estimate revision: reduce exposure if revenue growth decelerates materially versus prior-quarter trend or if gross-margin guidance is cut, as either would challenge the recurring-consumables operating-leverage thesis.
• Monitor DXCM and ABT as second-order beneficiaries, but do not add exposure solely on PODD momentum; confirmation requires evidence that pump adoption is expanding total CGM sensor usage rather than shifting patients among pump platforms.